Guardant Health Stock Jumps on Strong Revenue Beat and Raised Forecast

Shares of Guardant Health (GH) surged in after-hours trading after the liquid biopsy firm announced second-quarter 2026 financial results that surpassed analyst expectations and raised its full-year revenue outlook.

The company's stock jumped 8.8% in extended trading following the release, which outlined a powerful combination of strong current performance and management confidence in future growth.

Strong Q2 Results and Upgraded Outlook

Guardant Health reported total Q2 revenue of $335 million, a 44% increase year-over-year. This figure came in approximately 6.4% ahead of the Wall Street consensus estimate of about $314 million, representing a significant beat.

Buoyed by the strong results, the company raised its full-year 2026 revenue guidance to a new range of $1.34 billion to $1.36 billion. The midpoint of this forecast is roughly 3% higher than what analysts had previously modeled, signaling that management expects the current commercial momentum to continue.

Shield Test Fuels Growth

The standout performer in the quarter was the company's Shield colorectal cancer screening test. Key metrics for the segment include:

Ad

• Revenue: Approximately $52.9 million, an increase of over 250% year-over-year.
• Test Volume: Quadrupled compared to the same period last year.

This explosive growth was attributed to expanded insurance coverage and updated clinical guidelines, which have served as major catalysts. The company's core oncology business also demonstrated robust health, with revenue growing 38% to around $219 million, indicating broad strength across its portfolio.

Analyst Endorsement Adds to Momentum

Adding to the positive sentiment, analysts at Citi initiated coverage of Guardant Health on the same day with a Buy rating and a $215 price target. This fresh institutional endorsement amplified the market's reaction to the strong earnings print.

The combination of a decisive revenue beat, an upgraded forecast, and a bullish analyst initiation created a powerful convergence of catalysts, pushing the stock toward its 52-week high of $174.08.